COH:ASX
Cochlear Ltd
A$137.66
arrow_upward
+3.82%(+5.06) 1D
Sep 21, 11:38:40 AM GMT+10 · AUD
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for COH...
Open
A$133.53
High
A$139.21
Low
A$133.12
Mkt. cap
9.00B
Avg. vol.
759.49K
Volume
90.69K
Dividend
2.51%
Quarterly dividend
A$0.86
Ex-dividend date
Sep 21, 2026
P/E ratio
61.25
52-wk high
A$296.50
52-wk low
A$88.74
EPS
A$2.25
Shares outstanding
65.40M
No. of employees
5K
Open
A$133.53
High
A$139.21
Low
A$133.12
Mkt. cap
9.00B
Avg. vol.
759.49K
Volume
90.69K
Dividend
2.51%
Quarterly dividend
A$0.86
Ex-dividend date
Sep 21, 2026
P/E ratio
61.25
52-wk high
A$296.50
52-wk low
A$88.74
EPS
A$2.25
Shares outstanding
65.40M
No. of employees
5K
Profile
Cochlear is a medical device company that designs, manufactures, and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
Based in Sydney, Cochlear was formed in 1981 as a subsidiary of Nucleus with finance from the Australian government to commercialise the implants pioneered by Dr. Graeme Clark, although the company later became separate. As of 2022, the company holds 50% of the cochlear implant market, with more than 250,000 people receiving one of Cochlear's implants as of 2015.
Cochlear was named Australia's most innovative company by the Intellectual Property Research Institute of Australia in 2002 and 2003, and one of the world's most innovative companies by Forbes in 2011. Wikipedia
About Cochlear Ltd
CEODig Howitt
Employees5.4K
Founded1981
HeadquartersSydney, New South Wales, Australia
SectorMedical device
Websitecochlear.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in AUD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 583.60M | 583.60M | 590.20M | 590.20M |
Cost of goods sold | 159.60M | 159.60M | 184.40M | 184.40M |
Cost of revenue | 159.60M | 159.60M | 184.40M | 184.40M |
Research and development expenses | 76.40M | 76.40M | 85.20M | 85.20M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 224.70M | 224.70M | 239.40M | 239.40M |
Operating expense | 297.85M | 297.85M | 321.20M | 321.20M |
Total operating expenses | 457.45M | 457.45M | 505.60M | 505.60M |
Operating income | 126.15M | 126.15M | 84.60M | 84.60M |
Other non operating income | - | - | - | - |
EBT including unusual items | 106.55M | 106.55M | 400.00K | 400.00K |
EBT excluding unusual items | 128.25M | 128.25M | 86.55M | 86.55M |
Income tax expense | 25.80M | 25.80M | 7.50M | 7.50M |
Effective tax rate | 24.21% | 24.21% | 1,875.00% | 1,875.00% |
Other operating expenses | -3.25M | -3.25M | -3.40M | -3.40M |
Net income | 80.75M | 80.75M | -7.10M | -7.10M |
Net profit margin | 13.84% | 13.84% | -1.20% | -1.20% |
Earnings per share | - | - | - | - |
Interest and investment income | 4.20M | 4.20M | 900.00K | 900.00K |
Interest expense | -3.15M | -3.15M | -3.45M | -3.45M |
Net interest expenses | 1.05M | 1.05M | -2.55M | -2.55M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 151.95M | 151.95M | 88.00M | 88.00M |
Gain or loss from assets sale | - | - | 5.80M | 5.80M |